54916-28-8

Usage

Uses

Used in Organic Synthesis:
4-ACETYL-4'-METHOXYDIPHENYL ETHER is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure and reactivity make it suitable for the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-ACETYL-4'-METHOXYDIPHENYL ETHER is used as a starting material or building block for the development of new drugs. Its potential therapeutic effects and diverse chemical properties make it a promising candidate for the discovery of novel therapeutic agents.
Used in Neuropharmacology:
4-ACETYL-4'-METHOXYDIPHENYL ETHER is used as a research tool in neuropharmacology to investigate its potential therapeutic effects on neurological disorders. Its ability to modulate neurotransmitter systems and influence neuronal function makes it a valuable compound for studying the underlying mechanisms of various neurological conditions.
Used in Antioxidant Research:
In the field of medicinal chemistry, 4-ACETYL-4'-METHOXYDIPHENYL ETHER is used as an antioxidant agent. Its ability to scavenge free radicals and protect cells from oxidative damage makes it a promising candidate for the development of antioxidant therapies to combat various diseases and conditions associated with oxidative stress.
Used in Antiviral Research:
4-ACETYL-4'-METHOXYDIPHENYL ETHER is also studied for its potential antiviral activities. Its ability to inhibit viral replication and protect cells from viral infections makes it a valuable subject of research for the development of new antiviral drugs and therapies.

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 150-76-5 4-methoxy-phenol 
• 99-90-1 para-bromoacetophenone 
• 1122-95-8 sodium 4-methoxyphenolate 
• 99-91-2 para-chloroacetophenone 
• 13329-40-3 4-Iodoacetophenone 
• 403-41-8 1-(4-Fluorophenyl)ethanol 
• 248256-02-2 (4-methoxyphenoxymethyl)-(4-fluorophenyl)-ketone 
• 100-19-6 (4-nitrophenyl)ethanone 
• 139-02-6 sodium phenoxide 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 77-78-1 dimethyl sulfate 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 

Downstream Products

• 1215-99-2 1-[4-(4-hydroxy-phenoxy)-phenyl]-ethanone 
• 620633-63-8 1-(3-Fluoro-phenyl)-3-[4-(4-methoxy-phenoxy)-phenyl]-propane-1,3-dione 
• 352286-26-1 (E)-(S)-2-ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid ethyl ester 
• 1367364-67-7 C₃₄H₂₅NO₃ 
• 717909-53-0 2-bromo-1-[4-(4-methoxy-phenoxy)-phenyl]-ethanone 
• 1093730-39-2 2-(4-(4-methoxyphenoxy)phenyl)-2-oxoacetic acid 
• 947548-36-9 3-(4-(4-methoxyphenoxy)phenyl)-3-oxopropanal 
• 257609-02-2 1-(4-(4-(benzyloxy)phenoxy)phenyl)ethan-1-one 
• 10181-93-8 4-(4-methoxyphenoxy)phenol 
• 92549-44-5 [4-(4-methoxyphenoxy)phenyl]acetic acid 
• 393796-68-4 5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-5-[4-(4-methoxy-phenoxy)-phenyl]-pyrimidine-2,4,6-trione 
• 852631-26-6 5-bromo-5-[4-(4-methoxyphenoxy)phenyl]pyrimidine-2,4,6-trione 
• 852631-21-1 5-[4-(4-methoxyphenoxy)phenyl]pyrimidine-2,4,6-trione 
• 852631-17-5 [4-(4-methoxyphenoxy)phenyl]malonic dimethyl ester 

Relevant academic research and scientific papers

Identification of an Oxalamide Ligand for Copper-Catalyzed C?O Couplings from a Pharmaceutical Compound Library

A typical pharmaceutical compound library is stocked with molecular diversity and could provide a platform for the discovery of new ligand structures. Herein, we describe the use of this approach in combination with high throughput screening to identify N,N’-bis(thiophene-2-ylmethyl)oxalamide as a ligand that is generally effective for copper-catalyzed C?O cross-couplings to prepare both biarylethers as well as phenols under mild conditions.

Novel EDA transient electron donor-acceptor complex, and preparation method and applications thereof

The invention relates to a novel EDA transient electron donor-acceptor complex, and a preparation method and applications thereof. The structure of the complex is represented in the description, wherein R1 represents an electron-withdrawing group such as cyano, nitro, acetyl, trifluoromethyl, and the like; R2 represents any one substituent group such as hydrogen, an alkyl group (methyl, ethyl, etc.), chlorine, bromine, iodine, methoxyl, nitro, and the like; and the position of the substituent group can be an o-position, m-position, or p-position. According to the synthesis method, under the induction of visible light, phenol derivatives and electron deficient aryl halide carry out reactions under the action of basic cesium carbonate to generate the complex, and no transition metal catalyst, transition metal ligand, or photo oxidation-reduction agent is added. Through the reaction mechanism, a series of diaryl ether derivatives is prepared. The preparation method has the advantages of mild conditions, greenness, high efficiency, low cost, and simple operation.

A diaryl ether compounds of the novel preparation method and application thereof

The invention relates to a diaryl ether compounds of the novel preparation method, in particular compound is added to the reactor in sequence 1, dimethyl sulfoxide, cesium carbonate, compound 2, stirring at room temperature 10 - 60 minutes; then placing the reaction temperature is set to 70 - 120 °C the pot of the oil bath, and incandescent lamp for irradiation, the course of the reaction by TLC detection, to be after the reaction, the reaction solution by filtration, extraction and column chromatography, to obtain the target compound, the completion of the diaryl ether compound preparation. The technical scheme of the present invention visible under light induction, does not add any transition metal catalyst and ligand firmly oxidation reducing agent, aryl halide with phenol derivatives in photocatalytic C - O cross-coupling reaction. Preparation of mild conditions, green, high efficiency, low cost, simple and convenient operation. The preparation of this compound is a biological, medical, in the field of organic synthesis in particular pharmaceutical synthesis of important synthetic intermediate.

EDA (electronic design automation) transient electron donor-acceptor complex as well as preparation method and application thereof

The invention relates to an EDA (electronic design automation) transient electron donor-acceptor complex as well as a preparation method and application thereof. The compound has a structural formulashown in the specification, in the formula, R1 is an electron withdrawing group such as cyan, nitryl, acetyl and trifluoromethyl; R2 is any one of arbitrary substituent groups such as hydrogen, methyl, ethyl and other alkyl groups, chloro, bromo, iodo, methoxyl and nitryl; and the position relationship of the substituent groups is any one of an ortho-position, a meta-position and a para-position.According to a synthesis method, under induction of visible light, without addition of any transition metal catalyst, ligand or photoredox agent, the complex is prepared from a phenol derivative and an electron-deficient aryl halide under the action of alkali cesium carbonate through reactions. In addition, a series of diaryl ether derivatives are prepared through the reaction mechanism. The condition is gentle and green, the efficiency is high, the cost is low and operation is simple and convenient.

Method for preparing diaryl ether compound

The invention relates to a novel preparation method of a diaryl ether compound. The novel preparation method specifically comprises the following steps: sequentially putting a derivative of benzene, dimethyl sulfoxide, cesium carbonate and a phenol derivative into a reactor, and carrying out stirring for 30-60 minutes at room temperature; putting the mixture into an oil bath pot of which the reaction temperature is set as 70-120 DEG C, lighting the mixture with an incandescent light bulb, detecting the reaction process with TLC (thin layer chromatography), after the reaction is completed, carrying out filtering on a reaction liquid, and carrying out extraction and column chromatography, so as to obtain a target compound and complete preparation of the diaryl ether compound. By adopting thetechnical scheme of the invention, under induction of visible light, without addition of any transition metal catalyst, ligand or photoredox agent, an aryl halide and a phenol derivative are subjected to a photocatalytic C-O cross coupling reaction. The preparation method is mild in condition, green, efficient, low in cost and simple and convenient in operation. The prepared compound is a significant synthesis intermediate in fields such as biologics, medicines and organic synthesis, particularly in medicine synthesis.

Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors

Protein tyrosine phosphatase 1B (PTP1B) has been considered as a validated biological target for type 2 diabetes treatment, but past endeavors to develop inhibitors of PTP1B into drugs have been unsuccessful. Two challenging aspects are selective inhibition and cell permeability. A structure-based strategy was employed to develop uncharged bromophenols as a new series of PTP1B inhibitors. The most potent compound 22 (LXQ46) inhibited PTP1B with an IC50 value of 0.190 μM, and showed remarkable selectivity over other protein tyrosine phosphatases (PTPs, 20–200 folds). In the SPR study, increasing concentrations of compound 22 led to concentration-dependent increases in binding responses, indicating that compound 22 could bind to the surface of PTP1B via noncovalent means. By treating insulin-resistant C2C12 myotubes with compound 22, enhanced insulin and leptin signaling pathways were observed. Long-term oral administration of compound 22 reduced the blood glucose level of diabetic BKS db mice. The glucose tolerance tests (OGTT) and insulin tolerance tests (ITT) in BKS db mice showed that oral administration of compound 22 could increase insulin sensitivity. In addition, long-term oral administration of compound 22 could protect mice from obesity, which was not the result of toxicity. Our pharmacokinetics results from the rat-based assays showed that orally administered compound 22 was absorbed rapidly from the gastrointestinal tract, extensively distributed to the tissues, and rapidly eliminated from the body. All these results indicate that compound 22 could serve as a qualified agent to treat type II diabetes.

Nickel-catalyzed denitrative etherification of activated nitrobenzenes

Electron-deficient nitrobenzenes were coupled with phenols/alcohols to form diaryl/alkyl aryl ethers by the aid of NiCl2 as the catalyst. The reactions were conducted under ligand- and oxidant-free conditions without the exclusion of air or moisture. The initial studies upon the mechanism of the reaction revealed two solvent-dependent approaches. In molten TBAB, SNAr mechanism seems to be predominated, while, in DMF, the reaction might include the radical species.

Oxalic amide ligands, and uses thereof in copper-catalyzed coupling reaction of aryl halides

The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of C—N, C—O and C—S bonds.

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

Design, synthesis and biological evaluation of uncharged catechol derivatives as selective inhibitors of PTP1B

Protein tyrosine phosphatases 1B (PTP1B) is a promising and validated therapeutic target to effectively treat T2DM and obesity. However, the development of charged PTP1B inhibitors was restricted due to their low cell permeability and poor bioavailability. Based on active natural products, two series of uncharged catechol derivatives were identified as PTP1B inhibitors by targeting a secondary aryl phosphate-binding site as well as the catalytic site. The most potent inhibitor 22 showed an IC50 of 0.487?μM against PTP1B and strong selectivity (27-fold) over TCPTP. Kinetic studies were also performed that 22 act as a competitive PTP1B inhibitor. The treatment of C2C12 myotubes with 22 markedly increased the phosphorylation levels of IRβ, Akt and IRS1 phosphorylation. The similarity of its action profiling with that produced by insulin suggested its potential as a new non-insulin-dependent drug candidate.